First-year mortality after antiretroviral therapy initiation among people living with HIV/AIDS in Guangdong from 2016 to 2018

CHEN Xiu-yuan; ZHANG Yu-qin; ZHANG Jing; JIA Wei-dong; XIE Jin-zhao; CAI Wei-ping; GU Jing; LI Ling-hua; HAO Yuan-tao

doi:10.16462/j.cnki.zhjbkz.2022.06.005

Volume 26 Issue 6

Jun. 2022

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2022 > 26(6): 645-650

CHEN Xiu-yuan, ZHANG Yu-qin, ZHANG Jing, JIA Wei-dong, XIE Jin-zhao, CAI Wei-ping, GU Jing, LI Ling-hua, HAO Yuan-tao. First-year mortality after antiretroviral therapy initiation among people living with HIV/AIDS in Guangdong from 2016 to 2018[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(6): 645-650. doi: 10.16462/j.cnki.zhjbkz.2022.06.005

Citation:

CHEN Xiu-yuan, ZHANG Yu-qin, ZHANG Jing, JIA Wei-dong, XIE Jin-zhao, CAI Wei-ping, GU Jing, LI Ling-hua, HAO Yuan-tao. First-year mortality after antiretroviral therapy initiation among people living with HIV/AIDS in Guangdong from 2016 to 2018[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(6): 645-650. doi: 10.16462/j.cnki.zhjbkz.2022.06.005

Citation:

CHEN Xiu-yuan, ZHANG Yu-qin, ZHANG Jing, JIA Wei-dong, XIE Jin-zhao, CAI Wei-ping, GU Jing, LI Ling-hua, HAO Yuan-tao. First-year mortality after antiretroviral therapy initiation among people living with HIV/AIDS in Guangdong from 2016 to 2018[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(6): 645-650. doi: 10.16462/j.cnki.zhjbkz.2022.06.005

PDF( 1046 KB)

First-year mortality after antiretroviral therapy initiation among people living with HIV/AIDS in Guangdong from 2016 to 2018

doi: 10.16462/j.cnki.zhjbkz.2022.06.005

CHEN Xiu-yuan¹,
ZHANG Yu-qin¹,
ZHANG Jing¹,
JIA Wei-dong²,
XIE Jin-zhao¹,
CAI Wei-ping²,
GU Jing^{1, 3, 4},
LI Ling-hua^{2
,
,},
HAO Yuan-tao^{1, 3, 4, 5
,
,}

1.
Department of Medical Statistics, School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China
2.
Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou 510080, China
3.
Center of Global Health Research, Sun Yat-Sen University, Guangzhou 510300, China
4.
Center for Health Information Research, Sun Yat-sen University, Guangzhou 510300, China
5.
Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing 100191, China

Funds:

National Science and Technology Major Project of China 2018ZX10715004

More Information

Corresponding author: LI Ling-hua, E-mail: llheliza@126.com; HAO Yuan-tao, E-mail: haoyt@bjmu.edu.cn
Received Date: 2021-12-01
Rev Recd Date: 2022-02-15

Available Online: 2022-06-16

Publish Date: 2022-06-10

Abstract

Abstract

Objective To estimate the trends in first-year mortality among HIV/AIDS patients newly receiving antiretroviral therapy (ART) in Guangdong Province from 2016 to 2018. To compare the differences in mortality among HIV/AIDS patients from different regions in Guangdong during the"Guangdong AIDS Community Integrated Prevention and Treatment Research Project". Methods We estimated the annual first-year mortality after ART and standardized mortality ratio (SMR) of HIV/AIDS patients receiving ART at Guangzhou Eighth People's Hospital. And we analyzed the changes in patients'treatment characteristics using Cochran-Armitage tests. Finally, we explored the differences in first-year mortality of HIV/AIDS patients from different regions using Cox regressions. Results During 2016-2018, a total of 6 447 HIV/AIDS patients newly started ART. The number of patients in Guangzhou demonstration districts, other districts in Guangzhou and other cities in Guangdong Province were 976, 3 921, and 1 550, among that 152 people died. From 2016 to 2018, first-year mortality in Guangzhou demonstration districts decreased by 79.7%. The mortality in other districts in Guangzhou did not decline significantly, and the mortality of patients in other Cities in Guangdong increased by 18.8%. After standardization, SMR of three groups of patients all decreased.Among three groups, the early-diagnosis rates increased by year. But only HIV/AIDS patients living in Guangzhou had significant improvement in treatment outcome over the year. Cox regressions showed that after adjusting for baseline characteristics and factors being well controlled during the program implementation, differences in mortality rates no longer existed among patients in the three residence groups. Conclusions The first-year mortality of HIV/AIDS patients receiving ART in Guangzhou was well-controlled, especially patients from demonstration districts. But patients in other cities in Guangdong had high mortality, which could be explained by their poor physical conditions. For patients with HIV/AIDS receiving ART in Guangzhou but living in other cities in Guangdong Province, to focus on the poor ART outcomes and actively promote early treatment are crucial in reducing their first-year mortality.
- AIDS,
- Antiretroviral therapy,
- Mortality,
- Temporal trends

FullText(HTML)

References(11)

References

[1]	中华人民共和国国家卫生健康委员会. 2020年全国法定传染病疫情概况[EB/OL]. (2021-03-12) [2021-12-01]. http://www.nhc.gov.cn/jkj/s3578/202103/f1a448b7df7d4760976fea6d55834966.shtml. National Health Commission of the People's Republic of China. Overview of the National Epidemic of Notifiable Infectious Diseases in 2020 [EB/OL]. (2021-03-12) [2021-12-01]. http://www.nhc.gov.cn/jkj/s3578/202103/f1a448b7df7d4760976fea6d55834966.shtml.
[2]	中华人民共和国国家卫生健康委员会. 国家卫生计生委办公厅关于调整艾滋病免费抗病毒治疗标准的通知[EB/OL]. (2016-06-15) [2021-12-01]. http://www.nhc.gov.cn/yzygj/s3593/201606/0b0fa78e10dc41328e842b1bf9cd433e.shtml. National Health Commission of the People's Republic of China. Notice of the General Office of the National Health Commission on Adjusting the Standard of Free Antiretroviral Treatment for AIDS [EB/OL]. (2016-06-15) [2021-12-01]. http://www.nhc.gov.cn/yzygj/s3593/201606/0b0fa78e10dc41328e842b1bf9cd433e.shtml.
[3]	Brown AE, Kall MM, Smith RD, et al. Auditing national HIV guidelines and policies: The United Kingdom CD4 Surveillance Scheme [J]. Open AIDS J, 2012, 6: 149-155. DOI: 10.2174/1874613601206010149.
[4]	Munthali T, Michelo C, Mee P, et al. Survival of children living with HIV on art in Zambia: a 13-years retrospective cohort analysis [J]. Front Public Health, 2020, 8: 96. DOI: 10.3389/fpubh.2020.00096.
[5]	深圳市卫生健康委员会. 十三五国家科技重大专项广东省艾滋病病毒性肝炎等社区综合防治示范区项目在罗湖区启动[EB/OL]. (2019-03-22) [2021-12-01]. http://wjw.sz.gov.cn/xxgk/gzdt/content/post_3158976.html. Shenzhen Municipal Health Commission. The 13th Five-Year National Science and Technology Major Project Guangdong Province was launched in Luohu District [EB/OL]. (2019-03-22) [2021-12-01]. http://wjw.sz.gov.cn/xxgk/gzdt/content/post_3158976.html.
[6]	中国疾病预防控制中心. 全国疾病监测系统死因监测数据集[EB/OL]. (2021-01-11) [2021-12-01]. https://ncncd.chinacdc.cn/xzzq_1/202101/t20210111_223706.htm. Chinese Center for Disease Control and Prevention. Disease Surveillance System Cause of Death Surveillance Dataset in China [EB/OL]. (2021-01-11) [2021-12-01]. https://ncncd.chinacdc.cn/xzzq_1/202101/t20210111_223706.htm.
[7]	Zhang F, Dou Z, Ma Y, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study [J]. Lancet Infect Dis, 2011, 11(7): 516-524. DOI: 10.1016/s1473-3099(11)70097-4.
[8]	Zhu H, Napravnik S, Eron JJ, et al. Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China, 2003-2009 [J]. J Acquir Immune Defic Syndr, 2013, 63(5): e150-157. DOI: 10.1097/qai.0b013e3182948d82.
[9]	Croxford S, Kitching A, Desai S, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort [J]. Lancet Public Health, 2017, 2(1): e35-e46. DOI: 10.1016/s2468-2667(16)30020-2.
[10]	Liu WD, Tsai WC, Hsu WT, et al. Impact of initiation of combination antiretroviral therapy according to the WHO recommendations on the survival of HIV-positive patients in Taiwan [J]. J Microbiol Immunol Infect, 2020, 53(6): 936-945. DOI: 10.1016/j.jmii.2019.03.008.
[11]	Bisson GP, Ramchandani R, Miyahara S, et al. Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults [J]. AIDS, 2017, 31(16): 2217-2225. DOI: 10.1097/qad.0000000000001606.